CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-08-18). The draft was written by AI, the existence of all 1 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.7.
Verdict No. 2729 · Search date 2026-08-18 · Methodology v0.7

Vosoritide,
does it really help with Increased annualized growth velocity over 52 weeks in children with achondroplasia?

30-Second Summary
C
Evidence Grade C · 50 · Safety caution
Vosoritide increased 52-week growth velocity but did not establish adult height, function, or complication outcomes
All 119 treated participants reported an adverse event, but no treatment-related serious adverse event or death occurred. Daily injections, transient hypotension, and injection-site reactions require monitoring.
What the
research shows
The grade is C with 50 points. In a 121-patient double-blind placebo-controlled trial, the 52-week change in annualized growth velocity was 1.57 cm/year greater with vosoritide (95% CI 1.22 to 1.93; P<.0001). The difference was large by statistical convention, but the primary outcome was one-year growth velocity rather than adult height, function, or complications, and evidence came from one BioMarin-funded trial.
What the
ads claim
A one-year growth-velocity difference cannot be restated as improved adult height, mobility, self-care, spinal stenosis, or sleep apnea. The original report also stated that adult height and long-term harms were unknown.
*

Useful facts when choosing a product

  • The trial is registered as NCT03197766 and EudraCT 2015-003836-11.
  • All 119 treated participants reported at least one adverse event.
  • No treatment-related serious adverse event or death was reported.
Gap Measurement · Verdict 2729 · C 50
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

At 24 sites, 121 children aged 5 to under 18 were randomized to vosoritide, 60, or placebo, 61. Randomization used a voice or web-response system, and participants, investigators, and the sponsor were masked. The adjusted primary difference was 1.57 cm/year (95% CI 1.22 to 1.93). With no validated clinical threshold, magnitude was classified by statistical convention. From the interval, SE=(1.93−1.22)/(2×1.96)=0.181, SD=0.181/√(1/60+1/61)=1.00, and d≈1.58. Cross-checking the reported change SDs of 1.71 and 1.74 gave d≈0.91. The adjusted and raw-data calculations differed, but both exceeded Cohen 0.5. Enrollment below 200 was counted as one limitation. BioMarin Pharmaceutical funded the study.

02

Why this is classified as C (50)

A large 52-week growth-velocity difference was limited by an intermediate outcome, one manufacturer-funded trial, and enrollment below 200, giving C with 50 points.

Counterpoint. Final height, function, complications, and long-term safety were not conclusions of this 52-week trial.

Rejudgment record. Cross-check applied — Cross-checked the Lancet report and NCT03197766 for the adjusted primary result, randomization and masking, analysis counts, BioMarin funding, reported standard deviations, and unmeasured long-term outcomes

Scoring profile behind this grade
EndpointSSurrogate marker - laboratory or imaging measures
ReplicationR1Single confirmatory trial
IndependenceI0Evidence comes only from manufacturer studies
Effect sizeE+Meets the clinically important threshold

The scoring table and the verdict agree (C).

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Increased annualized growth velocity at 52 weeksCThe adjusted difference was 1.57 cm/year.
Improved adult height, function, or complications?The 52-week trial did not measure these outcomes.

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Study 1Double-blind placebo-controlled phase 3 randomized trial at 24 sites119BioMarin PharmaceuticalChange from baseline in annualized growth velocity at week 52Adjusted difference 1.57 cm/year (95% CI 1.22 to 1.93; P<.0001); no treatment-related serious adverse event or deathSingle manufacturer-funded trial with an intermediate outcome
§

Receipt — 1 References

All 1 cited sources were verified for existence at the original page (as of 2026-08-18).

Savarirayan R, Tofts L, Irving M, et al. Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial. Lancet. 2020;396(10252):684-692. PMID: 32891212. DOI: 10.1016/S0140-6736(20)31541-5. NCT03197766.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-08-18 · Corrections: none

Cite this verdict

Vosoritide x growth velocity in pediatric achondroplasia Evidence Grade C card
[Chamgap] Vosoritide x growth velocity in pediatric achondroplasia — Evidence Grade C·50. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/joint-bone/vosoritide-pediatric-achondroplasia-annualized-growth-velocity/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.